Inactive Instrument
Company Progenics Pharmaceuticals, Inc.
Stocks
US7431871067
Biotechnology & Medical Research
Business description: Progenics Pharmaceuticals, Inc.
Sales by Activity: Progenics Pharmaceuticals, Inc.
| Fiscal Period: December | 2019 (USD) |
|---|---|
Pharmaceuticals | 34.99M |
Executive Committee: Progenics Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
David Mims
CEO | Chief Executive Officer | 62 | - |
Company details: Progenics Pharmaceuticals, Inc.
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.59% | -3.35% | +64.49% | +98.69% | 70.64B | |
| -1.34% | -0.75% | +48.56% | +90.63% | 66.11B | |
| -8.37% | -12.43% | +0.14% | -15.42% | 27.98B | |
| -2.35% | -5.75% | -12.17% | +448.29% | 26.51B | |
| +0.30% | -0.69% | +63.18% | +11.93% | 26.44B | |
| -0.96% | +10.36% | +278.86% | +438.78% | 20.4B | |
| -0.51% | +0.23% | +33.71% | -18.02% | 20.17B | |
| -1.91% | -4.37% | +13.33% | +531.29% | 15.99B | |
| -1.47% | +0.68% | +43.67% | +145.49% | 13.69B | |
| Average | -2.02% | +0.19% | +59.31% | +192.41% | 31.99B | |
| Weighted average by Cap. | -1.98% | +0.11% | +56.60% | +152.15% |
